Quotes: MENA   Enter Symbol: NewsLetter: Search: advanced

Server is busy please try again later.  Join our daily free Newsletter

MENAFN Press - 17/10/2012
No. of Ratings : 0
Add to Mixx!



Due to technical reasons, this story has been removed from our database.

About CytoDyn Inc
CytoDyn is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses and other antibody applications. Its proprietary drug candidate Cytolin(R) is a monoclonal antibody that binds to CD11a, a cellular antigen that is a component of the cellular adhesion molecule LFA-1. CytoDyn intends to explore the clinical development of Cytolin(R) for persons infected with the Human Immunodeficiency Virus ('HIV") to determine if it could perturb the natural course of HIV infection. CytoDyn recently completed a humanized antibody construct of Cytolin(R), filed a provisional patent for its use, and manufacturing discussions are underway. In addition, CytoDyn is exploring the possible application of its existing proprietary monoclonal antibody for the treatment of Feline Immunodeficiency Virus ("FIV"), a retroviral infection in cats. CytoDyn recently filed for a provisional patent for the use of these antibodies as well as selected small molecule antagonists and agonists for the treatment of FIV, and filed an application for registration of the trademark CytoFeline, intended for use in conjunction with veterinary preparations for the treatment of FIV. For more information about Cytolin(R), CytoFeline(TM) and CytoDyn please go to www.cytodyn.com.Forward-Looking StatementsThis press release includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent CytoDyn's intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond CytoDyn's control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words "believe," "estimate," "expect," "intend," "attempt," "anticipate," "foresee," "plan," and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. CytoDyn disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information.While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on our products and product candidates will be unfavorable; our products will not receive marketing approval from regulators or, if approved, fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial potential of our products; CytoDyn, our collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.We are also subject to additional risks and uncertainties, including risks associated with the actions of our corporate, academic and other collaborators and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property, litigation, environmental and other risks; and risks that current and pending patent protection for our products may be invalid, unenforceable or challenged, or fail to provide adequate market exclusivity. There are also substantial risks arising out of our need to raise additional capital to develop our products and satisfy our financial obligations; the highly regulated nature of our business, including government cost-containment initiatives and restrictions on third-party payments for our products; the highly competitive nature of our industry; and other factors set forth in our Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.

 


MENAFN Press




  MENA News Headlines
 Apr 25 2015 - Dubai's Damac Q1 net profit down 38 percentMENAFN
(MENAFN) Dubai's Damac Properties reported a 38 percent fall in first-quarter net profit, despite surging revenue, because of the effect of a big one-off gain a year ago, Emirates 24/7 reported.The ...

 Apr 25 2015 - Saudi Cable signs USD170.7m debt restructure dealMENAFN
(MENAFN) Saudi Cable Company said in a statement that it has signed a deal with three of its main lenders to restructure USD170.7 million of debt, Arab News reported.The debt will be restructured ...

 Apr 25 2015 - Saudi petrochemical firms combined profit down in Q1MENAFN
(MENAFN) Saudi Arabia's first-quarter corporate earnings were generally weaker than expected, a sign that foreign investors should be cautious as the stock market opens up to them this year, Arab ...

 Apr 25 2015 - EU migrant rescue ships head for LibyaThe Peninsula
(MENAFN - The Peninsula) British and German warships made ready to sail for waters off Libya as Europe ramped up rescue operations in the Mediterranean after up to 900 desperate migrants drowned last ...

 Apr 25 2015 - Qatar- Al Rayyan thrash Al Markhiya as Emir Cup kicks off in styleThe Peninsula
(MENAFN - The Peninsula) Football giants Al Rayyan yesterday celebrated their ascent to Qatar Stars League (QSL) by crushing Markhiya 5-0 in their opening Emir Cup clash.Al Rayyan were demoted to the ...

 Apr 25 2015 - Qatar- 'Desert King' Al Attiyah is unstoppable on home soilThe Peninsula
(MENAFN - The Peninsula) Qatar's Nasser Saleh Al Attiyah, Spain's Marc Coma and Poland's Rafal Sonik each confirmed their third victories at the Sealine Cross-Country Rally in four years in the car, ...

 Apr 25 2015 - Qatar- Al Attiyah wins Sealine RallyThe Peninsula
(MENAFN - The Peninsula) Dakar Rally champion Nasser Saleh Al Attiyah yesterday said healthy time lead on the first three days set up his title win at this week's Sealine Cross-Country Rally. The ...

 Apr 25 2015 - Qatar- Stafford Sri Lankan School Doha celebrates New YearThe Peninsula
(MENAFN - The Peninsula) Stafford Sri Lankan School Doha celebrated the Sinhala and Hindu New Year recently by organising many traditional dances, games and competitions. The celebration, which ...

 Apr 25 2015 - Qatar- North Indians' Association celebrates BaisakhiThe Peninsula
(MENAFN - The Peninsula) North Indians' Association celebrated the harvest festival Baisakhi recently at Al Ghazal hall. Nearly 200 members joined the cultural programme organised by the association ...

 Apr 25 2015 - Qatar- Visa trading is illegal and punishableThe Peninsula
(MENAFN - The Peninsula) Qatari law sets strict punishment for visa traders with aim of preventing trade of illegal visas because every single illegal work visa adds an unemployed worker. If he/she ...

more...


 






Google

Internatinal Property Show

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country

Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Economic Calendar
Financial Glossary


Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2014 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help